Berkeley Lights Launches Beacon Select™, A New Optofluidic System For Cell Line Development
January 9, 2023
New, two-chip, single-cell optofluidic system ideal for small- to mid-sized biopharma & CDMOs/CROs to affordably gain access to the Beacon® technology and cell line development-specific applications EMERYVILLE, Calif. -- Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced the launch of the Beacon Select™, the company's new optofluidic system for cell line development (CLD). The [...]
Quanterix Announces Appointment Of Brian Blaser To Board Of Directors
January 9, 2023
BILLERICA, Mass. – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023. Mr. Blaser brings over 25 years of senior leadership experience in the in-vitro diagnostics industry, including 15 years at Abbott Laboratories where he was responsible [...]
January 9, 2023
Eschborn - Germany - AnalytiChem Holding GmbH today has announced the acquisition of bioTRADING Benelux B.V., a Dutch manufacturer of high-quality culture media in all forms of packaging. Founded in 1979, bioTRADING Benelux B.V. serves customers in a wide range of industries from pharmaceutical, veterinarian and food industries to hospitals, pharmacies and also supplies to regional [...]
Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen
January 9, 2023
Whole-genome sequencing of 35,000 de-identified, diverse genomic DNA samples will begin this month SAN DIEGO -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence [...]
January 9, 2023
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE: A) today announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong [...]
January 9, 2023
Company Announces Commercial Shipments of Protein Sequencing System, Reveals New Partnerships, and Reaffirms Commitment to Financial Discipline Launched in December 2022, Platinum is the First Commercially Available Next-Generation Single-Molecule Protein Sequencing System Looking to Unlock the Proteome One Amino Acid at a Time GUILFORD, Conn. -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein [...]
January 9, 2023
Protein Enrichment Kits to Enable Deep Interrogation of Proteoforms through Protein Sequencing GUILFORD, Conn. -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with an extensive portfolio of over [...]
PacBio and the University of Tokyo Announce Bioinformatics Applications Collaboration
January 9, 2023
MENLO PARK, Calif. -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a collaboration with the University of Tokyo, Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese population. [...]
Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement
January 9, 2023
RADNOR, Pa. and SOMERSET, N.J. -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc. (NYSE: CTLT), the leader in enabling the development [...]
Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration
January 9, 2023
SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a research collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) to discover antibodies against multiple targets of interest to develop curative therapies for [...]

